A sweeping healthcare reform act aimed at capping out-of-pocket prescription drug costs for all Americans has hit a massive roadblock on the Senate floor. A coordinated filibuster by opposition lawmakers has effectively stalled the bill indefinitely.
The legislation, which smoothly passed the House last month, faced stiff resistance in the upper chamber. Opponents argue that the price caps would stifle pharmaceutical innovation and lead to severe drug shortages nationwide.
Frustrated supporters of the bill held a press conference outside the Senate chamber, accusing their colleagues of prioritizing corporate lobbying over patient welfare. Senate leadership is currently attempting to negotiate a scaled-back version of the bill to bypass the 60-vote threshold.